Corporate governance
A global team of industry professionals with a track record in bringing innovation to market is developing a new technology in the loco-regional therapy of solid tumors.
- Consiglio di Amministrazione / Board of Directors
- Collegio sindacale / Statutory Auditors
- Società di revisione / Auditing firm
- Modello 231/2001 e Organismo di Vigilanza / Organizational Model 231/2001 and Supervisory Board
Consiglio di Amministrazione / Board of Directors
- RICCARDO PALMISANO (Presidente / Chairman)
- COLIN JOHN STORY (CEO)
- MICHEL ROGER RENE’ JOSE’ THERIN
- CLAUDIO GIULIANO
- DIANA SARACENI
- LUCA MELINDO
- GIOVANNI CERUTTI
Collegio sindacale / Statutory Auditors
- DANIEL VEZZANI (Presidente / President of the Board of Statutory Auditors)
- MAURIZIO GILI (Sindaco effettivo / Effective Statutory Auditor)
- MARCO CURTI (Sindaco effettivo / Effective Statutory Auditor)
- STEFANO PAGNIELLO (Sindaco supplente / Alternate Statutory Auditor)
- CLAUDIO VALPREDA (Sindaco supplente / Alternate Statutory Auditor)
Società di revisione / Auditing firm
- AUDIREVI S.P.A.
Modello 231/2001 e Organismo di Vigilanza / Organizational Model 231/2001 and Supervisory Board
BetaGlue Technologies in a Nutshell:
Localized Internal β-emitting
Radiotherapy
A new anti-tumoral compound based on 90Y β-emitting microspheres, embedded in a glue matrix and delivered to target with a dedicated delivery system.
The amount of energy needed is administered locally with a simple, intra-operative method.
The amount of energy needed is administered locally with a simple, intra-operative method.
ADMINISTRATION OF RADIONUCLIDES
Our technology allows a highly controlled administration of radionuclides directly into the tumoral mass.
It achieves the highest efficacy where it is needed, while at the same time minimizing the risk of unwanted side effects, both locally and in the entire patient’s body.
DELIVERY SYSTEM
Administration device engineered to guarantee a precise delivery of the required dose of energy where it is needed, thus overcoming some disadvantages of external beam radiation therapy (EBRT).
MULTIPLE
APPLICATIONS
The applications of this β-emitting radiotherapy platform is currently being developed to treat unresectable primary hepatocellular carcinoma (HCC).
Additional applications for other loco-regional treatments are being researched.
Contact us
